Loading...

UCB SA

UCBJFPNK
Healthcare
Biotechnology
$199.89
$0.00(0.00%)

UCB SA (UCBJF) Stock Overview

Explore UCB SA’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap38B
P/E Ratio138.51
EPS (TTM)$6.29
ROE0.03%
Fundamental Analysis

AI Price Forecasts

1 Week$184.60
1 Month$179.48
3 Months$136.05
1 Year Target$298.68

UCBJF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of UCB SA (UCBJF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $298.68.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 138.51 and a market capitalization of 38B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
17.14%
17.14%
Profit Growth
$1.22
210.50%
EPS Growth
$1.22
209.94%
Operating Margin
9.15%
119.21%
ROE
2.53%
210.50%
Dividend Yield
0.00%
2.67%

Analyst Recommendations

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

CEO

Jean-Christophe Tellier

Employees

9,052

Headquarters

Allée de la Recherche, 60, Brussels

Founded

2008

Frequently Asked Questions

;